Search

Your search keyword '"Van Griethuysen J"' showing total 6 results
Start Over "Van Griethuysen J" Publisher elsevier b.v.
6 results on '"Van Griethuysen J"'

2. PO-0981: Results from the Image Biomarker Standardisation Initiative

Author

Zwanenburg, A., Abdalah, M.A., Apte, A., Ashrafinia, S., Beukinga, J., Bogowicz, M., Dinh, C.V., Götz, M., Hatt, M., Leijenaar, R.T.H., Lenkowicz, J., Morin, O., Rao, A.U.K., Socarras Fernandez, J., Vallières, M., Van Dijk, L.V., Van Griethuysen, J., Van Velden, F.H.P., Whybra, P., Troost, E.G.C., Richter, C., and Löck, S.

Published
2018
Full Text
View/download PDF

4. A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy.

Author

Lerner, A., Lee, A.J.X., Yan, H., Van Griethuysen, J., Bartlett, A.D., Veli, M., Jiang, Y., Luong, M., Naban, N., Kane, C., Conibear, J., Papadatos-Pastos, D., Ahmad, T., Chao, D., Anand, G., and Asghar, U.S.

Subjects
*THERAPEUTIC use of monoclonal antibodies, *LUNG cancer, *RESEARCH, *IMMUNE checkpoint inhibitors, *SPECIALTY hospitals, *DIARRHEA, *CONFIDENCE intervals, *RETROSPECTIVE studies, *METASTASIS, *EXANTHEMA, *CANCER patients, *TREATMENT effectiveness, *CANCER treatment, *SEVERITY of illness index, *PROGRESSION-free survival, *IMMUNOTHERAPY, *LONGITUDINAL method, *OVERALL survival, *DRUG toxicity, *PROPORTIONAL hazards models
Abstract

We present 7 years of clinical experience with single-agent pembrolizumab immune checkpoint inhibitor immunotherapy in non-small cell lung cancers (NSCLC) from four UK cancer centres. This multi-institutional retrospective cohort study included 226 metastatic NSCLC patients. Outcomes were number and severity of immune-related adverse events (irAEs), median progression-free survival (mPFS) and median overall survival (mOS). Within our cohort, 119/226 (53%) patients developed irAEs. Of these, 54/119 (45%) experienced irAEs affecting two or more organ systems. The most common irAEs were diarrhoea and rash. The development of an irAE was associated with better mOS (20.7 versus 8.0 months; P < 0.001) and mPFS (12.0 versus 3.9 months; P < 0.001). The development of grade 3/4 toxicities was associated with worse outcomes compared with the development of grade 1/2 toxicities (mOS 6.1 months versus 25.2 months, P < 0.01; mPFS 5.6 months versus 19.3 months, P = 0.01, respectively). Females had a higher proportion of reported grade 3/4 toxicities (13/44 [29.5%] versus 10/74 [13.5%], P = 0.03). Using a multiple Cox regression model, the presence of irAEs was associated with a better overall survival (hazard ratio = 0.42, 95% confidence interval 0.29–0.61; P < 0.01) and better PFS (hazard ratio 0.38, 95% confidence interval 0.27–0.53; P < 0.001). In this multicentre retrospective cohort study, the development of at least one irAE was associated with significantly longer mPFS and mOS; however, more severe grade 3 and 4 irAEs were associated with worse outcomes. Delayed-onset irAEs, after the 3-month timepoint, were associated with better clinical outcomes. • Multi-institution experience (n = 226) of pembrolizumab monotherapy in advanced lung cancer. • Development of immune-related adverse events (irAEs) associated with improved outcomes. • Onset of irAEs at >3 months from treatment start associated with better outcomes. • Patients with CTCAE grade 1–2 toxicity did better than those with grade 3–4 toxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. 446 - Long-term follow-up features on rectal MRI during a ‘watch-and-wait’ approach in clinical complete responders after chemoradiotherapy: an update of 140 patients.

Author

Lambregts, D., Maas, M., Delli Pizzi, A., Van der Sande, M., Van Heeswijk, M., Hupkens, B., Beckers, R., Van Griethuysen, J., Lahaye, M., Beets, G., and Beets-Tan, R.

Subjects
*CANCER chemotherapy, *LONGITUDINAL method, *MAGNETIC resonance imaging, *RADIOTHERAPY, *TREATMENT effectiveness, *DIAGNOSIS, *TUMOR treatment, RECTUM tumors
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results